Nuvelo, Inc. Announces Second Quarter 2007 Financial Results and Accomplishments Conference Call

SAN CARLOS, Calif., July 19 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced that it will hold a conference call to discuss its second quarter 2007 financial results and accomplishments on Thursday, August 2, 2007, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).

To participate in the conference call, please dial 866-825-1709 for domestic callers and 617-213-8060 for international callers and reference conference passcode 80512181. A telephone replay of the conference call will be available through Thursday, August 16, 2007. To access the replay, please dial 888-286-8010 for domestic callers and 617-801-6888 for international callers and reference conference passcode 73047735. In addition, this call is being webcast by Thomson/CCBN and can be accessed via Nuvelo’s website at www.nuvelo.com.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson’s individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo’s development pipeline includes three acute cardiovascular programs: alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic-related disorders including acute ischemic stroke, catheter occlusion and acute peripheral arterial occlusion; rNAPc2, an anticoagulant that inhibits the factor VIIa and tissue factor protease complex that completed Phase 2 clinical development in acute coronary syndromes; and preclinical candidate NU172, a direct thrombin inhibitor for use as a short- acting anticoagulant during medical or surgical procedures. Nuvelo is also advancing an emerging oncology pipeline, including rNAPc2 which is in Phase 2 testing for potential use as a cancer therapy, as well as NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to leverage its expertise in secreted proteins and cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities. Information about Nuvelo is available at our website at www.nuvelo.com or by phoning 650-517-8000.

Nuvelo Contacts: Nicole Foderaro Director of Corporate Communications & IR 650-517-8472 nfoderaro@nuvelo.com

Nuvelo, Inc.

CONTACT: Nicole Foderaro, Director of Corporate Communications & IR, ofNuvelo, Inc., +1-650-517-8472, nfoderaro@nuvelo.com

MORE ON THIS TOPIC